Literature DB >> 11822762

Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management.

D Rades1, G Kühnel, I Wildfang, A R Börner, H J Schmoll, W Knapp.   

Abstract

BACKGROUND: Two to four percent of cancer patients present with CUP syndrome. Median survival for localised disease is 20 and for disseminated disease, seven months. For localised disease, curative treatment is more likely and individual therapeutic strategies become more important. After conservative diagnostic procedures including MRI, the primary is detected in less than 25%. The diagnostic value of PET and its influence on therapeutic strategies was evaluated. PATIENTS AND METHODS: Forty-two patients with localised CUP were investigated from 5 of 98 to 10 of 2000. The presenting site was lymph node metastasis in 34 and visceral metastasis in 8 patients. After a median of 7 (3-11) diagnostic procedures without detection of the primary, but evidence of localised disease, PET was performed with fluorine-18-fluorodeoxyglucose.
RESULTS: In 26 of 42 patients (62%), a primary was suggested by PET and confirmed in 18 (43%). In 5 of 18 patients beyond localised disease, additional dissemination, not detected by previous diagnostic measures, was diagnosed by PET. Overall, dissemination was only detected only by PET in 16 of 42 patients (38%). In29 of 42 patients (69%), the PET result influenced selection of the definitive treatment.
CONCLUSION: In CUP patients, PET has a certain impact on detection of the primary as well as of the disseminated disease. and may also have a certain impact on therapeutic management.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11822762     DOI: 10.1023/a:1013107732572

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  19 in total

1.  Is whole-body FDG-PET valuable for health screening? For.

Authors:  Michiru Ide; Yutaka Suzuki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03       Impact factor: 9.236

2.  Iliac lymph node metastasis of an unknown primary tumor: report of a case.

Authors:  Satoru Matsuyama; Yuji Nakafusa; Masayuki Tanaka; Yukie Yoda; Daisuke Mori; Kohji Miyazaki
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

Review 3.  Diagnosis and management of neck metastases from an unknown primary.

Authors:  L Calabrese; B A Jereczek-Fossa; J Jassem; A Rocca; R Bruschini; R Orecchia; F Chiesa
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-02       Impact factor: 2.124

Review 4.  [Metastases with CUP syndrome].

Authors:  S Seeber; D Strumberg
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

5.  Carcinoma of Unknown Primary - an Orphan Disease?

Authors:  Alwin Krämer; Gerdt Hübner; Andreas Schneeweiss; Gunnar Folprecht; Kai Neben
Journal:  Breast Care (Basel)       Date:  2008-06-19       Impact factor: 2.860

6.  The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary origin.

Authors:  Clare L Scott; Iveta Kudaba; Josephine M Stewart; Rodney J Hicks; Danny Rischin
Journal:  Mol Imaging Biol       Date:  2005 May-Jun       Impact factor: 3.488

7.  Utility of F-18 fluorodeoxyglucose posıtron emıssıon tomography/computed ın carcınoma of unknown primary.

Authors:  Umut Elboga; Selim Kervancioğlu; Ertan Sahin; Mustafa Basibuyuk; Y Zeki Celen; Cumali Aktolun
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

8.  [Carcinoma of unknown primary site (CUP syndrome)].

Authors:  A Sendler; D Strumberg; A Tannapfel
Journal:  Chirurg       Date:  2008-07       Impact factor: 0.955

9.  18-FDG PET in the diagnosis of laterocervical metastases from occult carcinoma.

Authors:  Davide Padovani; Claudia Aimoni; Pietro Zucchetta; Alessandro Paluzzi; Antonio Pastore
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06-28       Impact factor: 2.503

Review 10.  Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.

Authors:  Sebastián Moran; Anna Martinez-Cardús; Stergios Boussios; Manel Esteller
Journal:  Nat Rev Clin Oncol       Date:  2017-07-04       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.